• Yungjin Pharm plans a 1-for-5 share consolidation, reducing outstanding common shares from 182,892,731 to 36,578,546.
• Par value will rise from KRW 500 to KRW 2,500 per share to maintain an appropriate number of shares in circulation.
• The board decided on November 3, 2026; shareholder approval is scheduled for December 11, 2026.
• The consolidation takes effect January 12, 2027, with new shares scheduled to list February 2, 2027.
• Trading will be suspended from January 8 through February 1, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yungjin Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261103800530), on November 03, 2026, and is solely responsible for the information contained therein.